Crescita Therapeutics Reports Fourth Quarter and Fiscal 2018 Results Record Annual Revenue of $16.6M and Adjusted EBITDA of $1.5M Strong Royalties and Sales Milestones

Stock Information for Crescita Therapeutics Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Crescita Therapeutics Inc.

Crescita Reports 2019 Third Quarter Results
U.S. Food and Drug Administration Approves Enhanced Formulation of Pliaglis®
Sundial and Crescita Sign Exclusive Partnership to Develop Cannabis and Hemp Topicals
Crescita Therapeutics Inc. to Present at the Fall Investor Summit on September 16th-17th in New York City
Crescita Reports Profitable 2019 Second Quarter Results
United States Patent and Trademark Office Issues U.S. Patent Covering an Enhanced Formulation of Pliaglis®
Crescita Therapeutics to Host Investor Webcast on July 24, 2019
Crescita Therapeutics Inc. Receives 2nd Instalment of Up-Front Payment of Euro1.25 Million Following First Commercial Sale of Pliaglis by Cantabria in Italy

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.